Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1/2 16Phase 1 6Phase 3 5Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 19Completed 13Recruiting 7Not yet recruiting 7Active not recruiting 6Terminated 5Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Malignant Tumor of Pancreas Metastatic to Liver 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 5Leucovorin 5Fluorouracil 5Gemcitabine 4pirarubicin 2liposomal doxorubicin 2Surgical Procedures, Operative 2Radiation 2Paclitaxel 2Neoadjuvant Therapy 2Folfox protocol 2Capecitabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2vocimagene amiretrorepvec 1taxane 1sulindac sulfone 1remdesivir 1pembrolizumab 1nimotuzumab 1methylnaltrexone 1lenvatinib 1irinotecan sucrosofate 1carbon-11 acetate 1bavituximab 1alovudine 1aflibercept 1Thyroxine 1Therapeutics 1Temozolomide 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Capecitabine × Clear all
NCT04037241 2022-04-01

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Sorrento Therapeutics, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Malignant Tumor of Pancreas Metastatic to Liver

NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡